Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Biology Laboratory, |
RCV000625531 | SCV001425203 | pathogenic | Polycystic kidney disease, adult type | 2020-02-01 | criteria provided, single submitter | research | |
Gene |
RCV005001090 | SCV005626569 | pathogenic | not provided | 2024-07-10 | criteria provided, single submitter | clinical testing | Observed in patients with polycystic kidney disease in published literature and referred for testing at GeneDx (PMID: 33532864, 30816285); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30816285, 33532864) |
Fulgent Genetics, |
RCV000625531 | SCV005640605 | pathogenic | Polycystic kidney disease, adult type | 2024-05-14 | criteria provided, single submitter | clinical testing | |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000625531 | SCV000746026 | likely pathogenic | Polycystic kidney disease, adult type | 2017-09-18 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004740374 | SCV005362754 | pathogenic | PKD1-related disorder | 2024-08-31 | no assertion criteria provided | clinical testing | The PKD1 c.896_897delCT variant is predicted to result in a frameshift and premature protein termination (p.Pro299Argfs*71). This variant was reported in individuals with autosomal dominant polycystic kidney disease (ADPKD) (Supplementary Table 2 of Pandita et al. 2019. PubMed ID: 30816285; Supplementary Table 2 of Domingo-Gallego et al. 2022. PubMed ID: 33532864). This variant has not been reported in a large population database, indicating this variant is rare. Frameshift variants in PKD1 are expected to be pathogenic. This variant is interpreted as pathogenic. |